Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Teaching | 1 | 2018 | 55 | 0.650 |
Why?
|
| Neoplasms | 2 | 2018 | 608 | 0.620 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 207 | 0.600 |
Why?
|
| Internship and Residency | 1 | 2018 | 283 | 0.510 |
Why?
|
| Breast Neoplasms | 5 | 2017 | 666 | 0.410 |
Why?
|
| Anthracyclines | 4 | 2017 | 51 | 0.350 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 546 | 0.320 |
Why?
|
| Thalidomide | 1 | 2007 | 29 | 0.300 |
Why?
|
| Scalp | 2 | 2017 | 33 | 0.290 |
Why?
|
| Alopecia | 2 | 2017 | 25 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2017 | 401 | 0.270 |
Why?
|
| Esophageal Neoplasms | 3 | 2006 | 33 | 0.210 |
Why?
|
| Taxoids | 3 | 2017 | 47 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 4 | 2017 | 56 | 0.170 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 47 | 0.170 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 16 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 161 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2018 | 307 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2006 | 56 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 117 | 0.130 |
Why?
|
| Adult | 12 | 2017 | 8391 | 0.130 |
Why?
|
| Radiopharmaceuticals | 2 | 2006 | 87 | 0.130 |
Why?
|
| Humans | 16 | 2018 | 29013 | 0.130 |
Why?
|
| Aged | 12 | 2017 | 9462 | 0.130 |
Why?
|
| Aged, 80 and over | 8 | 2013 | 3712 | 0.130 |
Why?
|
| Middle Aged | 12 | 2017 | 10805 | 0.130 |
Why?
|
| Adenocarcinoma | 4 | 2006 | 301 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 206 | 0.130 |
Why?
|
| Quality of Life | 2 | 2017 | 815 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 641 | 0.120 |
Why?
|
| Female | 14 | 2017 | 18114 | 0.110 |
Why?
|
| Leukemia | 1 | 2013 | 36 | 0.110 |
Why?
|
| Lymphoma | 1 | 2013 | 36 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 62 | 0.110 |
Why?
|
| Colorectal Neoplasms | 2 | 2007 | 208 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 2 | 2005 | 131 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2017 | 163 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 337 | 0.090 |
Why?
|
| Aorta | 1 | 2009 | 103 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2013 | 3099 | 0.080 |
Why?
|
| European Continental Ancestry Group | 1 | 2013 | 1131 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2007 | 50 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 38 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2007 | 169 | 0.070 |
Why?
|
| Lymphatic Metastasis | 3 | 2014 | 156 | 0.070 |
Why?
|
| Camptothecin | 2 | 2005 | 48 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2005 | 63 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 1007 | 0.070 |
Why?
|
| Male | 9 | 2013 | 17768 | 0.070 |
Why?
|
| African Americans | 1 | 2013 | 1373 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2017 | 2010 | 0.070 |
Why?
|
| Survival Rate | 4 | 2013 | 795 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 2006 | 524 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2002 | 73 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 281 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 784 | 0.040 |
Why?
|
| Medical Illustration | 1 | 2017 | 7 | 0.040 |
Why?
|
| Cryotherapy | 1 | 2017 | 12 | 0.040 |
Why?
|
| Photography | 1 | 2017 | 33 | 0.040 |
Why?
|
| Headache | 1 | 2017 | 74 | 0.040 |
Why?
|
| Young Adult | 2 | 2013 | 2398 | 0.040 |
Why?
|
| Risk | 1 | 2017 | 289 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2006 | 98 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2014 | 3107 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 142 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2014 | 45 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 89 | 0.030 |
Why?
|
| Ergocalciferols | 1 | 2013 | 3 | 0.030 |
Why?
|
| Troponin I | 1 | 2013 | 17 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 2013 | 8 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 56 | 0.030 |
Why?
|
| Mastectomy | 1 | 2013 | 59 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 262 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 199 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 194 | 0.030 |
Why?
|
| Age Factors | 1 | 2014 | 1105 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2013 | 278 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 1997 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2106 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 22 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2007 | 26 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 855 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 1218 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 84 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 159 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2006 | 15 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 13 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 25 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 32 | 0.020 |
Why?
|
| Vomiting | 1 | 2005 | 24 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 68 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 3509 | 0.020 |
Why?
|
| Nausea | 1 | 2005 | 49 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 38 | 0.020 |
Why?
|
| Diarrhea | 1 | 2005 | 56 | 0.020 |
Why?
|
| Fatigue | 1 | 2005 | 68 | 0.020 |
Why?
|
| Adolescent | 1 | 2013 | 3248 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 172 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 246 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 436 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 636 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 724 | 0.010 |
Why?
|
| Ethnic Groups | 1 | 2006 | 440 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 572 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 12 | 0.010 |
Why?
|
| Leucovorin | 1 | 2002 | 20 | 0.010 |
Why?
|
| Neutropenia | 1 | 2002 | 23 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 2002 | 15 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 67 | 0.010 |
Why?
|
| Methotrexate | 1 | 2002 | 60 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2002 | 92 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2005 | 1674 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 162 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 384 | 0.010 |
Why?
|